Neonatal Hypoglycemia

Neonatal Hypoglycemia

No Results

No Results


Neonatal hypoglycemia, defined as a plasma glucose level of less than 30 mg/dL (1.65 mmol/L) in the first 24 hours of life and less than 45 mg/dL (2.5 mmol/L) thereafter, is the most common metabolic problem in newborns. Major long-term sequelae include neurologic damage resulting in mental retardation, recurrent seizure activity, developmental delay, and personality disorders. Some evidence suggests that severe hypoglycemia may impair cardiovascular function.

The image below depicts normal hypoglycemic counterregulation.

Infants in the first or second day of life may be asymptomatic or may have life-threatening central nervous system (CNS) and cardiopulmonary disturbances. Symptoms can include the following:


Lethargy, apathy

Poor feeding

Jitteriness, seizures

Congestive heart failure




Clinical manifestations associated with activation of the autonomic nervous system include the following:

Anxiety, tremulousness




Hunger, nausea, and vomiting

Clinical manifestations of hypoglycorrhachia or neuroglycopenia include the following:


Mental confusion, staring, behavioral changes, difficulty concentrating

Visual disturbances (eg, decreased acuity, diplopia)



Ataxia, somnolence, coma

Stroke (hemiplegia, aphasia), paresthesias, dizziness, amnesia, decerebrate or decorticate posturing

See Clinical Presentation for more detail.

Laboratory studies

Serum or plasma glucose levels

Serum insulin

Urine: Obtain a first-voided urine dipstick for ketones; send urine for organic acid analysis

Screening for metabolic errors: Electrospray ionization-tandem mass spectrometry in asymptomatic persons allows earlier identification of clearly defined inborn errors of metabolism, including aminoacidemias, urea cycle disorders, organic acidurias, and fatty acid oxidation disorders


The detection of adenomas by celiac angiography has had limited success. The chance of detecting a tumor blush must be balanced against the potential risk of causing vascular trauma in infants younger than 2 years.

See Workup for more detail.

Hypoglycemia should be treated as soon as possible to prevent complications of neurologic damage. Early feeding of the newborn with breast milk or formula is encouraged. The mainstay of therapy for children who are alert with intact airway protection includes orange juice at 20 mL/kg.

For patients who cannot protect their airway or are unable to drink, nasogastric, intramuscular, intraosseous, or intravenous (IV) routes can be employed for the following drugs used to raise glucose levels: dextrose, glucagon, diazoxide, and octreotide. Start a 5% or 10% dextrose drip when hypoglycemia is recurrent.


Surgical exploration usually is undertaken in severely affected neonates who are unresponsive to glucose and somatostatin therapy. Near-total resection of 85-90% of the pancreas is recommended for presumed congenital hyperinsulinism, which is most commonly associated with an abnormality of beta-cell regulation throughout the pancreas. Risks include the development of diabetes.

See Treatment and Medication for more detail.

Hypoglycemia is the most common metabolic problem in neonates. In children, a blood glucose value of less than 40 mg/dL (2.2 mmol/L) represents hypoglycemia. A plasma glucose level of less than 30 mg/dL (1.65 mmol/L) in the first 24 hours of life and less than 45 mg/dL (2.5 mmol/L) thereafter constitutes hypoglycemia in the newborn.

Patients with hypoglycemia may be asymptomatic or may present with severe central nervous system (CNS) and cardiopulmonary disturbances. The most common clinical manifestations can include altered level of consciousness, seizure, vomiting, unresponsiveness, and lethargy. Any acutely ill child should be evaluated for hypoglycemia, especially when history reveals diminished oral intake. (See History and Physical Examination.)

Sustained or repetitive hypoglycemia in infants and children has a major impact on normal brain development and function. Evidence suggests that hypoxemia and ischemia potentiate hypoglycemia, causing brain damage that may permanently impair neurologic development. (See Prognosis.)

Causes of hypoglycemia in neonates differ slightly from those in older infants and children. The causes in neonates include the following (see Etiology):

Inappropriate changes in hormone secretion

Inadequate substrate reserve in the form of hepatic glycogen

Inadequate muscle stores as a source of amino acids for gluconeogenesis

Inadequate lipid stores for the release of fatty acids

Hyperinsulinism, or persistent hyperinsulinemic hypoglycemia of infancy (PHHI), is the most common cause of hypoglycemia in the first 3 months of life. It is well recognized in infants of mothers with diabetes. (See Etiology.)

Causes of hypoglycemia found in all ages include gram-negative sepsis, endotoxin shock, and ingestions, including of salicylates, alcohol, hypoglycemic agents, or beta-adrenergic blocking agents.

Excluding insulin therapy, almost all hypoglycemia in childhood occurs during fasting. Postprandial hypoglycemia is rare in children in the absence of prior gastrointestinal (GI) surgery. Management efforts are directed toward the immediate normalization of glucose levels and the identification and treatment of the various causes. (See Treatment and Medications.)

Provide genetic counseling for families with affected children, including information about a possible 25% risk of recurrence. Educate pregnant women with diabetes.

Normal blood glucose is very narrowly regulated, usually from 80-90 mg/dL (4.4-5 mmol/L). Glucose levels increase transiently after meals to 120-140 mg/dL (6.6-7.7 mmol/L). Feedback systems return the glucose concentration rapidly back to the preprandial level, usually within 2 hours after the last absorption of carbohydrates.

Insulin and glucagon are the important hormones in the immediate feedback control system of glucose. When blood glucose increases after a meal, the rate of insulin secretion increases and stimulates the liver to store glucose as glycogen. When cells (primarily liver and muscle) are saturated with glycogen, additional glucose is stored as fat.

When blood glucose levels fall, glucagon secretion functions to increase blood glucose levels by stimulating the liver to undergo glycogenolysis and release glucose back into the blood. (See the diagram below.)

In starvation, the liver maintains the glucose level via gluconeogenesis. Gluconeogenesis is the formation of glucose from amino acids and the glycerol portion of fat. Muscle provides a store of glycogen and muscle protein breaks down to amino acids, which are substrates utilized in gluconeogenesis in the liver. Circulating fatty acids are catabolized to ketones, acetoacetate, and B-hydroxybutyrate and can be used as auxiliary fuel by most tissues, including the brain.

The hypothalamus stimulates the sympathetic nervous system, and epinephrine is secreted by the adrenals, causing the further release of glucose from the liver. Over a period of hours to days of prolonged hypoglycemia, growth hormone and cortisol are secreted and decrease the rate of glucose utilization by most cells of the body.

In the newborn, serum glucose levels decline after birth until age 1-3 hours, then they spontaneously increase. Liver glycogen stores become rapidly depleted within hours of birth, and gluconeogenesis, primarily from alanine, can account for 10% of glucose turnover in the newborn infant by several hours of age.

The causes of neonatal hypoglycemia include the following:


Limited glycogen stores (eg, prematurity, intrauterine growth retardation)

Increased glucose use (eg, hyperthermia, polycythemia, sepsis, growth hormone deficiency)

Decreased glycogenolysis, gluconeogenesis, or use of alternate fuels (eg, inborn errors of metabolism, adrenal insufficiency)

Depleted glycogen stores (eg, asphyxia-perinatal stress, starvation)

With regard to the last item above, in ketotic hypoglycemia, easily depleted glycogen stores, in combination with inadequate production of glucose through gluconeogenesis, contribute to hypoglycemia. Thus, fatty acid oxygenation is required to provide substrate for gluconeogenesis and ketogenesis. Ketones, the byproduct of fatty acid metabolism, are found in urine and represent the starved state.

A study by Ogunyemi et al indicated that independent risk factors for neonatal hypoglycemia include macrosomia, cesarean section, lower gestational age, and treatment for chorioamnionitis. Small-for-gestational-age neonates are also at greater risk. The study included 318 neonates with hypoglycemia and 7955 controls. [1]

A retrospective study by Yamamoto et al indicated that in women with type 1 diabetes mellitus, large-for-gestational-age neonates have a 2.5-fold increased risk for hypoglycemia. The study looked at pregnancies in 161 women with type 1 diabetes. [2]

Causes of hypoglycemia in older infants, children, and teenagers include:

Poisonings/drugs (eg, ethanol, isoniazid, insulin, propranolol, salicylates, oral hypoglycemics, pentamidine, quinine, disopyramide, unripe ackee fruit, Vacor [rat poison]).

Liver disease (eg, Reye syndrome, hepatitis, cirrhosis, hepatoma)

Amino acid and organic acid disorders (eg, maple syrup urine disease, propionic acidemia, methylmalonic acidemia, tyrosinosis, glutaric aciduria, 3-hydroxy-3-methylglutaric aciduria)

Systemic disease (eg, sepsis, burns, cardiogenic shock, respiratory distress syndrome)

Congenital hyperinsulinism is most commonly associated with an abnormality of beta-cell regulation throughout the pancreas. A focal disease, such as isolated islet adenoma, occasionally causes congenital hyperinsulinism.

Genetic defects have been delineated and now replace the older terms, such as nesidioblastosis, leucine-sensitive hypoglycemia, PHHI, and islet dysregulation syndrome. These defects are in the sulfonylurea receptor (SUR) and the beta-cell potassium adenosine triphosphate (ATP) channel gene located on the short arm of chromosome 11.

Drug-induced hyperinsulinism is secondary to surreptitious insulin administration or the use of oral hypoglycemic drugs. Exogenous administration of insulin is diagnosed with low serum levels of C-peptide. The sulfonylureas are commonly prescribed for adults; thus, they are available to children as unintentional ingestions. In these cases, hypoglycemia may persist for more than 24 hours. Diazoxide administration may be helpful by suppressing insulin secretion in severe cases.

The overall incidence of symptomatic hypoglycemia in newborns varies from 1.3-3 per 1000 live births. Incidence varies with the definition, population, method and timing of feeding, and the type of glucose assay. Serum glucose levels are higher than whole blood values. The incidence of hypoglycemia is greater in high-risk neonatal groups (see History).

Early feeding decreases the incidence of hypoglycemia. Inborn errors of metabolism that lead to neonatal hypoglycemia are rare but can be screened in infancy. [3] The incidences of these conditions are as follows:

Carbohydrate metabolism disorders (>1:10,000)

Fatty acid oxidation disorders (1:10,000)

Hereditary fructose intolerance (1:20,000 to 1:50,000)

Glycogen storage diseases (1:25,000)

Galactosemia (1:40,000)

Organic acidemias (1:50,000)

Phosphoenolpyruvate carboxykinase deficiency (rare)

Primary lactic acidosis (rare)

In a Japanese study, more than 80% of admissions from the nursery to the neonatal intensive care unit (NICU) after birth were due to apnea or hypoglycemia in neonates born at 35-36 weeks’ gestation. [4]

Hypoglycemia is the most common metabolic problem in neonates. Still, the level or duration of hypoglycemia that is harmful to an infant’s developing brain is not known. Major long-term sequelae include neurologic damage resulting in mental retardation, recurrent seizure activity, developmental delay, and personality disorders. Some evidence suggests that severe hypoglycemia may impair cardiovascular function.

Although the occipital lobes, which contain the primary visual cortex and several extrastriate visual areas, may be especially vulnerable to the effects of neonatal hypoglycemia, a literature review by Paudel et al found the evidence as to whether neonatal hypoglycemia negatively impacts eye and optic nerve development to be inconclusive. [5]

Remission of congenital hyperinsulinism generally does not occur, but the severity of the disease may decrease with time.

Ogunyemi D, Friedman P, Betcher K, et al. Obstetrical Correlates and Perinatal Consequences of Neonatal Hypoglycemia in Term Infants. J Matern Fetal Neonatal Med. 2016 Jul 17. 1-16. [Medline].

Yamamoto JM, Kallas-Koeman MM, Butalia S, Lodha AK, Donovan LE. Large-for-Gestational-Age Neonate Predicts a 2.5-Fold Increased Odds of Neonatal Hypoglycemia in Women with Type 1 Diabetes. Diabetes Metab Res Rev. 2016 May 17. [Medline].

Raghuveer TS, Garg U, Graf WD. Inborn errors of metabolism in infancy and early childhood: an update. Am Fam Physician. 2006 Jun 1. 73(11):1981-90. [Medline].

Ishiguro A, Namai Y, Ito YM. Managing “healthy” late preterm infants. Pediatr Int. 2009 Oct. 51(5):720-5. [Medline].

Paudel N, Chakraborty A, Anstice N, et al. Neonatal Hypoglycaemia and Visual Development: A Review. Neonatology. 2017 Mar 3. 112 (1):47-52. [Medline].

Newborn Nursery QI Committee. Portland (ME): The Barbara Bush Children”s Hospital at Maine Medical Center; 2004 Jul. Neonatal hypoglycemia: initial and follow up management. National Guideline Clearinghouse. 2004. [Full Text].

Harris DL, Weston PJ, Harding JE. Incidence of neonatal hypoglycemia in babies identified as at risk. J Pediatr. 2012 Nov. 161(5):787-91. [Medline].

Narchi H, Skinner A, Williams B. Small for gestational age neonates–are we missing some by only using standard population growth standards and does it matter?. J Matern Fetal Neonatal Med. 2010 Jan. 23(1):48-54. [Medline].

Vanhaltren K, Malhotra A. Characteristics of infants at risk of hypoglycaemia secondary to being ‘infant of a diabetic mother’. J Pediatr Endocrinol Metab. 2013 May 17. 1-5. [Medline].

Rozance PJ, Hay WW Jr. New approaches to management of neonatal hypoglycemia. Matern Health Neonatol Perinatol. 2016. 2:3. [Medline]. [Full Text].

Joshi T, Oldmeadow C, Attia J, Wynne K. The duration of intrapartum maternal hyperglycaemia predicts neonatal hypoglycaemia in women with pre-existing diabetes. Diabet Med. 2017 Feb 15. [Medline].

Coors SM, Cousin JJ, Hagan JL, Kaiser JR. Prophylactic Dextrose Gel Does Not Prevent Neonatal Hypoglycemia: A Quasi-Experimental Pilot Study. J Pediatr. 2018 Mar 28. [Medline].

Makker K, Alissa R, Dudek C, Travers L, Smotherman C, Hudak ML. Glucose Gel in Infants at Risk for Transitional Neonatal Hypoglycemia. Am J Perinatol. 2018 Mar 26. [Medline].

Harris DL, Weston PJ, Signal M, Chase JG, Harding JE. Dextrose gel for neonatal hypoglycaemia (the Sugar Babies Study): a randomised, double-blind, placebo-controlled trial. Lancet. 2013 Sep 24. [Medline].

Lewis R. Inexpensive Dextrose Gel Corrects Hypoglycemia in Newborns. Sep 24 2013. Available at Accessed: Oct 2 2013.

Hilarie Cranmer, MD, MPH, FACEP Director of Disaster Response, MGH Center for Global Health; Attending Physician, Department of Emergency Medicine, Massachusetts General Hospital; Assistant Professor, Harvard Medical School and School of Public Health

Hilarie Cranmer, MD, MPH, FACEP is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, Massachusetts Medical Society, Physicians for Human Rights, Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Wayne Wolfram, MD, MPH Professor, Department of Emergency Medicine, Mercy St Vincent Medical Center; Chairman, Pediatric Institutional Review Board, Mercy St Vincent Medical Center, Toledo, Ohio

Wayne Wolfram, MD, MPH is a member of the following medical societies: American Academy of Emergency Medicine, American Academy of Pediatrics, Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

George T Griffing, MD Professor Emeritus of Medicine, St Louis University School of Medicine

George T Griffing, MD is a member of the following medical societies: American Association for the Advancement of Science, International Society for Clinical Densitometry, Southern Society for Clinical Investigation, American College of Medical Practice Executives, American Association for Physician Leadership, American College of Physicians, American Diabetes Association, American Federation for Medical Research, American Heart Association, Central Society for Clinical and Translational Research, Endocrine Society

Disclosure: Nothing to disclose.

Debra Slapper, MD Physician, Southwest Washington Free Clinic System-Urgent Care; Former FEMA Physician and Military Contractor; Former Associate Professor, University of Miami, Leonard M Miller School of Medicine and University of South Florida Morsani College of Medicine

Debra Slapper, MD is a member of the following medical societies: American Academy of Emergency Medicine

Disclosure: Nothing to disclose.

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author Michael Shannon, MD, MPH†,to the development and writing of the source article.

Neonatal Hypoglycemia

Research & References of Neonatal Hypoglycemia|A&C Accounting And Tax Services